Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Satnam Singh; Roger Beadle; Donnie Cameron; Amelia Rudd; Maggie Bruce; Baljit Jagpal; Konstantin Schwarz; Gemma Brindley; Fergus Mckiddie; Chim Lang; Dana Dawson; Michael Frenneaux

doi:10.2217/fca.14.62

Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Satnam Singh, Roger Beadle, Donnie Cameron, Amelia Rudd, Maggie Bruce, Baljit Jagpal, Konstantin Schwarz, Gemma Brindley, Fergus Mckiddie, Chim Lang, Dana Dawson, Michael Frenneaux (Lead / Corresponding author)

Research output: Contribution to journal › Article › peer-review

8 Citations (Scopus)

Abstract

Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

Original language	English
Pages (from-to)	693-698
Number of pages	6
Journal	Future Cardiology
Volume	10
Issue number	6
DOIs	https://doi.org/10.2217/fca.14.62
Publication status	Published - 1 Nov 2014

Keywords

cardiac spectroscopy
diastole
ejection fraction
heart failure
perhexiline

ASJC Scopus subject areas

Cardiology and Cardiovascular Medicine
Molecular Medicine

Access to Document

10.2217/fca.14.62

Cite this

@article{5998d548e91a4d0380f935631df05f37,

title = "Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome",

abstract = "Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.",

keywords = "cardiac spectroscopy, diastole, ejection fraction, heart failure, perhexiline",

author = "Satnam Singh and Roger Beadle and Donnie Cameron and Amelia Rudd and Maggie Bruce and Baljit Jagpal and Konstantin Schwarz and Gemma Brindley and Fergus Mckiddie and Chim Lang and Dana Dawson and Michael Frenneaux",

year = "2014",

month = nov,

day = "1",

doi = "10.2217/fca.14.62",

language = "English",

volume = "10",

pages = "693--698",

journal = "Future Cardiology",

issn = "1479-6678",

publisher = "Future Medicine",

number = "6",

}

TY - JOUR

T1 - Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

AU - Singh, Satnam

AU - Beadle, Roger

AU - Cameron, Donnie

AU - Rudd, Amelia

AU - Bruce, Maggie

AU - Jagpal, Baljit

AU - Schwarz, Konstantin

AU - Brindley, Gemma

AU - Mckiddie, Fergus

AU - Lang, Chim

AU - Dawson, Dana

AU - Frenneaux, Michael

PY - 2014/11/1

Y1 - 2014/11/1

N2 - Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

AB - Recently heart failure with preserved ejection fraction (HFpEF) has emerged as a huge epidemic. Increasing evidence shows the role of energy deficiency in the pathophysiology of HFpEF. In the current study, we hypothesize that the use of metabolic modulator perhexiline would correct myocardial energy deficiency and improve exercise capacity and diastolic abnormalities in patients with this syndrome.

KW - cardiac spectroscopy

KW - diastole

KW - ejection fraction

KW - heart failure

KW - perhexiline

UR - http://www.scopus.com/inward/record.url?scp=84919819995&partnerID=8YFLogxK

U2 - 10.2217/fca.14.62

DO - 10.2217/fca.14.62

M3 - Article

C2 - 25495811

AN - SCOPUS:84919819995

SN - 1479-6678

VL - 10

SP - 693

EP - 698

JO - Future Cardiology

JF - Future Cardiology

IS - 6

ER -

Randomized double-blind placebo-controlled trial of perhexiline in heart failure with preserved ejection fraction syndrome

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this